Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients

Published:2023-03-10 Issue:1 Volume:55 Page:1018-1028
ISSN:0785-3890
Container-title:Annals of Medicine
language:en
Short-container-title:Annals of Medicine

Author:

Gil Michał¹^ORCID,Knetki-Wróblewska Magdalena²^ORCID,Niziński Przemysław³^ORCID,Strzemski Maciej⁴^ORCID,Krawczyk Paweł¹^ORCID

Affiliation:

1. Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland

2. Department of Lung Cancer and Chest Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

3. Department of Pharmacology, Medical University of Lublin, Lublin, Poland

4. Department of Analytical Chemistry, Medical University of Lublin, Lublin, Poland

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07853890.2023.2187077

Reference59 articles.

1. Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)

2. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer

3. Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies

4. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer

5. Ettinger D Wood D Aisner D et al. Non-Small Cell Lung Cancer Version 3. 2022. J Natl Compr Canc Netw. 2022;20:497-530.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy;Medicine in Drug Discovery;2024-09

2. Clinical and Molecular Traits of a Novel SPECC1L-ALK Fusion in a Patient with Advanced Non-Small Cell Lung Cancer;Journal of Personalized Medicine;2024-06-21

3. Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC: Report of two cases;Current Problems in Cancer: Case Reports;2024-06

4. Managementul metastazelor cerebrale la pacienţii cu cancer pulmonar fără celule mici ALK-pozitiv;Oncolog-Hematolog.ro;2024

5. Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?;Current Oncology;2023-05-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3